These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 27624575)

  • 21. The autonomic balance predicts cardiac responses after the first dose of fingolimod.
    Rossi S; Rocchi C; Studer V; Motta C; Lauretti B; Germani G; Macchiarulo G; Marfia GA; Centonze D
    Mult Scler; 2015 Feb; 21(2):206-16. PubMed ID: 24957049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses.
    Chinea Martinez AR; Correale J; Coyle PK; Meng X; Tenenbaum N
    Adv Ther; 2014 Oct; 31(10):1072-81. PubMed ID: 25245812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis.
    Li K; Konofalska U; Akgün K; Reimann M; Rüdiger H; Haase R; Ziemssen T
    Front Neurosci; 2017; 11():540. PubMed ID: 29075174
    [No Abstract]   [Full Text] [Related]  

  • 24. Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study.
    Paolicelli D; Manni A; Direnzo V; D'Onghia M; Tortorella C; Zoccolella S; Trojano M
    J Clin Pharmacol; 2015 Oct; 55(10):1131-6. PubMed ID: 25903516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.
    Ziemssen T; Kern R; Cornelissen C
    BMC Neurol; 2016 Aug; 16():129. PubMed ID: 27502119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B; Ross AP; Tobias K
    Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study.
    Papeix C; Castelnovo G; Leray E; Coustans M; Levy P; Visy JM; Kobelt G; Lamy F; Allaf B; Heintzmann F; Chouette I; Raponi E; Durand B; Grevat E; Kamar D; Debouverie M; Lebrun-Frenay C;
    Neurol Ther; 2022 Jun; 11(2):633-658. PubMed ID: 35147904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The outbreak fingolimod cardiovascular side effects in relapsing-remitting multiple sclerosis patient: A longitudinal study in an Iranian population.
    Abdar M; Ebrahimifar P; Etemadifar M
    ARYA Atheroscler; 2016 Nov; 12(6):274-280. PubMed ID: 28607567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heart rate variability predicts the magnitude of heart rate decrease after fingolimod initiation.
    Simula S; Laitinen TP; Laitinen TM; Hartikainen P; Hartikainen JE
    Mult Scler Relat Disord; 2016 Nov; 10():86-89. PubMed ID: 27919506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
    Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Swiss real world best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedure.
    Ramseier SP; Roth S; Czaplinski A
    BMC Pharmacol Toxicol; 2015 Apr; 16():7. PubMed ID: 25889400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis.
    Long M; Cross R; Calkwood J; Pondel M; Pai A; Ahmad H; Charles L; Elegbe A; Petersen A; Sheffield J; Javed A; Wolf D
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S9-S10. PubMed ID: 37461957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications.
    Camm J; Hla T; Bakshi R; Brinkmann V
    Am Heart J; 2014 Nov; 168(5):632-44. PubMed ID: 25440790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
    Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA
    J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initiating oral fingolimod treatment in patients with multiple sclerosis.
    Singer BA
    Ther Adv Neurol Disord; 2013 Jul; 6(4):269-75. PubMed ID: 23858329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delayed cardiac dysrhythmias after fingolimod administration.
    Rosini JM; Rajasimhan S; Fellows SE; Nomura JT
    Am J Emerg Med; 2015 Jul; 33(7):987.e1-3. PubMed ID: 25669873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac repolarization evolves differently during the course of benign and disabling multiple sclerosis.
    Mikkola A; Ojanen A; Hartikainen JE; Remes AM; Simula S
    Mult Scler Relat Disord; 2018 Feb; 20():205-209. PubMed ID: 29428463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis.
    Yavari F; Oliazadeh P; Radfar M; Foroughipour M; Nikkhah K; Heidari Bakavoli A; Saeidi M
    Basic Clin Neurosci; 2021; 12(2):233-242. PubMed ID: 34925720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): An observational study in the UK.
    Mazibrada G; Sharples C; Perfect I
    Mult Scler J Exp Transl Clin; 2018; 4(4):2055217318801638. PubMed ID: 30327723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.